GotoPER - Physicians' Education Resource
Back to Home
Free CE/CMEVideo

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Create AccountAlready Registered? Login Here

Release Date

July 11, 2025

Expiration Date

July 12, 2026

Credits

2.0 CME, NCPD

Specialties

Breast Cancer, Medical Oncology+3 more

Release Date: July 11, 2025

Expiration Date: July 11, 2026

Activity Overview

This educational activity is an archive of the live presentation held on Friday, May 30, 2025.

For more information about this educational activity, the faculty, and disclosures, please click here.

Target Audience

This educational activity is directed toward medical oncologists, nurses, nurse practitioners, physician assistants, and other health care providers involved in the treatment and management of metastatic breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Assess clinical trial evidence for antibody-drug conjugates in the management of HR+/HER2–, HER2+, and triple-negative breast cancer (TNBC)
  • Develop patient-centered treatment plans for advanced/metastatic breast cancer
  • Evaluate strategies for sequencing of antibody-drug conjugates in the management of HR+/HER2–, HER2+, and TNBC
  • Implement effective toxicity management approaches to optimize outcomes and minimize adverse events for patients receiving ADCs and targeted therapies for HR+/HER2–, HER2+, and TNBC
Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

GET STARTED WITH THIS PROGRAM:

Register now to gain access to this program.

Create AccountAlready Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Gilead Sciences, Inc; and Helsinn.

Related Content

Course

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Create Account